3Q EARNINGS: AbbVie beats profit estimates on higher Humira sales
This article was originally published in Scrip
Executive Summary
US drug company AbbVie said 19% sales growth of its Humira therapy for autoimmune diseases helped it beat Wall Street estimates for third-quarter profit.